

CITATION REPORT

List of articles citing

Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial

DOI: 10.1016/s1665-2681(19)32103-9
Annals of Hepatology, 2004, 3, 108-112.

Source: <https://exaly.com/paper-pdf/36308809/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
48	Esteatosis hepática y resistencia a la insulina: ¿quién ocurre primero?. <i>Clinica E Investigaci3n En Arteriosclerosis</i> , 2006 , 18, 72-82	1.4	
47	Nonalcoholic Fatty Liver Disease (NAFLD): Approach in the Adolescent Patient. <i>Current Treatment Options in Gastroenterology</i> , 2006 , 9, 423-31	2.5	17
46	Present and future therapeutic strategies in non-alcoholic fatty liver disease. <i>Expert Opinion on Therapeutic Targets</i> , 2007 , 11, 1231-49	6.4	39
45	Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. <i>The Cochrane Library</i> , 2007 , CD005360	3.6	21
44	Medical treatment of non-alcoholic steatohepatitis. <i>Clinics in Liver Disease</i> , 2007 , 11, 119-40, ix	4.6	26
43	Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 293-303	4	123
42	Treating nonalcoholic fatty liver disease. <i>Liver International</i> , 2007 , 27, 1157-65	7.9	15
41	Neue Therapiem3glichkeiten bei nichtalkoholischer Fettleber. <i>Diabetologe</i> , 2007 , 3, 202-210	0.2	1
40	Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 13-24	6.1	104
39	Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. <i>Pharmacological Reviews</i> , 2008 , 60, 311-57	22.5	288
38	The trials and tribulations of the treatment of nonalcoholic fatty-liver disease. <i>Current Opinion in Lipidology</i> , 2008 , 19, 592-9	4.4	4
37	Physical Activity and Nonalcoholic Fatty Liver Disease. <i>Annals of Hepatology</i> , 2009 , 8, 273-274	3.1	
36	Treatment regimens for non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2009 , 8, S51-S59	3.1	36
35	Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2009 , 48, 587-96	2.8	74
34	Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Paediatric Population. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2009 , 3, 94-101		
33	Nonviral Hepatitis. <i>Journal of Pharmacy Practice</i> , 2009 , 22, 388-404	1.3	5
32	Current status of therapy in nonalcoholic Fatty liver disease. <i>Therapeutic Advances in Gastroenterology</i> , 2009 , 2, 29-43	4.7	9

31	Identification and treatment of metabolic complications in pediatric obesity. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2009 , 10, 167-88	10.5	44
30	Bile acids and insulin resistance: implications for treating nonalcoholic fatty liver disease. <i>Journal of Digestive Diseases</i> , 2009 , 10, 85-90	3.3	32
29	Effect of body weight and lifestyle changes on long-term course of nonalcoholic fatty liver disease in Koreans. <i>American Journal of the Medical Sciences</i> , 2009 , 337, 98-102	2.2	53
28	A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 52, 79-104	11.2	399
27	Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. <i>International Journal of Clinical Practice</i> , 2010 , 64, 968-83	2.9	32
26	Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. <i>Obesity</i> , 2010 , 18, 1762-7	8	42
25	Weight reduction for non-alcoholic fatty liver disease. <i>The Cochrane Library</i> , 2011 , CD003619	5.2	35
24	Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. <i>Expert Opinion on Emerging Drugs</i> , 2011 , 16, 121-36	3.7	15
23	Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease. <i>Antioxidants and Redox Signaling</i> , 2011 , 15, 505-21	8.4	75
22	Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. <i>Current Vascular Pharmacology</i> , 2012 , 10, 162-72	3.3	42
21	Ursodeoxycholic acid for nonalcoholic steatohepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 1247-53	2.2	10
20	Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. <i>Diabetologia</i> , 2012 , 55, 885-904	10.3	444
19	Pharmacologic therapy for nonalcoholic fatty liver disease in adults. <i>Pharmacotherapy</i> , 2013 , 33, 223-42	5.8	11
18	Lifestyle interventions for the treatment of non-alcoholic fatty liver disease. <i>Hepatic Medicine: Evidence and Research</i> , 2014 , 6, 1-10	3.4	5
17	Use of ursodeoxycholic acid in patients with hypertransaminasemia. <i>Italian Journal of Medicine</i> , 2014 , 8, 141	0.5	
16	Pharmacologic Management of Non-Alcoholic Fatty Liver Disease. <i>Advances in Pharmacoeconomics & Drug Safety</i> , 2014 , 03,		1
15	A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. <i>Gastroenterology Research and Practice</i> , 2016 , 2016, 7109270	2	42
14	Endoplasmic reticulum stress and the development of endothelial dysfunction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017 , 312, H355-H367	5.2	52

13	Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. <i>The Cochrane Library</i> , 2017 , 3, CD011640	5.2	28
12	Both alcoholic and non-alcoholic steatohepatitis association with cardiovascular risk and liver fibrosis. <i>Alcohol</i> , 2018 , 69, 63-67	2.7	13
11	Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. <i>Postgraduate Medical Journal</i> , 2018 , 94, 556-565	2	11
10	Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials. <i>Pharmacological Research</i> , 2018 , 135, 144-149	10.2	18
9	Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. <i>Lipids in Health and Disease</i> , 2019 , 18, 88	4.4	14
8	Treatments of nonalcoholic fatty liver disease in adults who have no other illness: A Review article. <i>Arab Journal of Gastroenterology</i> , 2019 , 20, 189-197	1.7	1
7	Effect of ursodeoxycholic acid on liver markers: A systematic review and meta-analysis of randomized placebo-controlled clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1476-1488 ³⁸	3.8	8
6	Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease. <i>PLoS ONE</i> , 2016 , 11, e0152007	3.7	17
5	Ursodeoxycholic Acid: Efficacy and Safety in the Treatment of Nonalcoholic Fatty Liver Disease (Meta-Analysis). <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2018 , 73, 294-305	0.4	1
4	Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: a systematic review and meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> ,	4.2	0
3	A multi-centered trial investigating gestational treatment with ursodeoxycholic acid compared to metformin to reduce effects of diabetes mellitus (GUARD): a randomized controlled trial protocol. 2022 , 23,		
2	Obesity Management in the Primary Prevention of Hepatocellular Carcinoma. 2022 , 14, 4051		2
1	Ursodeoxycholic Acid in Liver Cirrhosis: A Chinese Perspective. 2022 , 81-111		0